DepoMed (DEPO) Sell-Off an 'Over-Reaction', Roth Capital Says; PT to $28.50

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. SKYD
6. BBIO
7. CRBU
8. FIGR
9. OPCH
10. NEOG

Go back to DepoMed (DEPO) Sell-Off an 'Over-Reaction', Roth Capital Says; PT to $28.50

Depomed Reports First Quarter 2015 Financial Results

May 11, 2015 4:06 PM EDT

NEWARK, Calif., May 11, 2015 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today reported financial results and highlighted operational achievements for the quarter ended March 31, 2015.

"Depomed is in a period of tremendous growth, on track to become one of the top five companies selling branded pain pharmaceuticals in the US by 2016," said Jim Schoeneck, President and CEO of Depomed. "The products we have acquired over the past three years continue to perform exceptionally well.  Gralise, Cambia and Lazanda delivered strong revenue and prescription growth in first quarter. Our experience integrating... More